We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
39 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Gavreto (pralsetinib) has been approved for the treatment of adult patients with advanced or metastatic RET-fusion positive thyroid cancer.
-
Prescription medicine decision summaryTGA decision: Gavreto (pralsetinib) is provisionally approved to treat adults with locally advanced or metastatic rearranged during transfection fusion-positive non-small cell lung cancer.
-
Australian Public Assessment Report (AusPAR)Vabysmo (faricimab) for the treatment of neovascular age-related macular degeneration and diabetic macular oedema.
-
-
Designation or determinationProvisional determination
-
Designation or determinationProvisional determination
-
Designation or determinationProvisional determination
-
Designation or determinationProvisional determination
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Casirivimab/imdevimab
-